Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.

Article Details

Citation

Copy to clipboard

Harenberg J, Wehling M

Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.

Semin Thromb Hemost. 2008 Feb;34(1):39-57. doi: 10.1055/s-2008-1066023.

PubMed ID

18393142 [ View in PubMed

]

Abstract

Indirect systemic and direct oral factor Xa and direct oral factor IIa inhibitors with improved pharmacologic profiles compared with heparins and vitamin K antagonists are currently in clinical development. This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran). Specifically, the results of dose-finding studies for the prevention of venous thromboembolism after elective orthopedic surgery, the results of dose-finding studies for treatment of acute venous thromboembolism including prolonged prophylaxis of recurrent events, and the designs of ongoing clinical trials are reviewed.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Apixaban	Coagulation factor X	Protein	Humans	Yes	Inhibitor	Details